Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EyePoint, Inc.EYPT · Entity 5702 | Chief Medical Officer | June 30, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EyePoint, Inc.
Report date June 30, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-06-30 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-06-30 · Exercise / conversion · Acquired 2,437 · Balance 2,437 Row 2 · 2026-06-30 · Exercise / conversion · Acquired 2,438 · Balance 4,875 Row 3 · 2026-06-30 · Sale · Disposed 2,437 · Balance 2,438 Row 4 · 2026-06-30 · Sale · Disposed 2,438 · Balance 0 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.06. The reporting person undertakes to provide EyePoint Inc., any security holder of EyePoint Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.26 · Expires 2035-01-03 | Direct | 78,001 |
Reported balance
After 2026-06-30 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-06-30 · Exercise / conversion · Disposed 2,437 · Balance 78,001 F2: The option to purchase will vest and become exercisable as follows: 25% at January 3, 2026 and the remainder ratably, on a monthly basis, over the remaining three years. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.26 · Expires 2035-01-03 | Direct | 75,563 |
Reported balance
After 2026-06-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-06-30 · Exercise / conversion · Disposed 2,438 · Balance 75,563 F2: The option to purchase will vest and become exercisable as follows: 25% at January 3, 2026 and the remainder ratably, on a monthly basis, over the remaining three years. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.06. The reporting person undertakes to provide EyePoint Inc., any security holder of EyePoint Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The option to purchase will vest and become exercisable as follows: 25% at January 3, 2026 and the remainder ratably, on a monthly basis, over the remaining three years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2026 Filed Jul 2, 2026 20:03 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,438 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0002013623-26-000012 · primarydocument.xml · derivative · entry 6 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,563 Underlying: Common Stock · 2,438 shares Expires 2035-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at January 3, 2026 and the remainder ratably, on a monthly basis, over the remaining three years. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:03 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,437 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0002013623-26-000012 · primarydocument.xml · derivative · entry 5 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,001 Underlying: Common Stock · 2,437 shares Expires 2035-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at January 3, 2026 and the remainder ratably, on a monthly basis, over the remaining three years. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:03 UTC | EyePoint, Inc. EYPT · Entity 5702 | SaleCommon Stock | 2,438 | $15.02 | $36,611.93 |
DisclosureSEC source: 0002013623-26-000012 · primarydocument.xml · nonDerivative · entry 4 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.06. The reporting person undertakes to provide EyePoint Inc., any security holder of EyePoint Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:03 UTC | EyePoint, Inc. EYPT · Entity 5702 | SaleCommon Stock | 2,437 | $15.00 | $36,555.00 |
DisclosureSEC source: 0002013623-26-000012 · primarydocument.xml · nonDerivative · entry 3 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,438 Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:03 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 2,438 | $8.26 | $20,137.88 |
DisclosureSEC source: 0002013623-26-000012 · primarydocument.xml · nonDerivative · entry 2 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:03 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 2,437 | $8.26 | $20,129.62 |
DisclosureSEC source: 0002013623-26-000012 · primarydocument.xml · nonDerivative · entry 1 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,437 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 17, 2026 Filed Apr 20, 2026 20:07 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,437 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0002013623-26-000010 · primarydocument.xml · derivative · entry 3 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,438 Underlying: Common Stock · 2,437 shares Expires 2035-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option to purchase vests and become exercisable as follows: 25% vested at January 3, 2026 and the remainder vests ratably, on a monthly basis, over the remaining three years. Read SEC document |
| April 17, 2026 Filed Apr 20, 2026 20:07 UTC | EyePoint, Inc. EYPT · Entity 5702 | SaleCommon Stock | 2,437 | $15.00 | $36,555.00 |
DisclosureSEC source: 0002013623-26-000010 · primarydocument.xml · nonDerivative · entry 2 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Read SEC document |
| April 17, 2026 Filed Apr 20, 2026 20:07 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 2,437 | $8.26 | $20,129.62 |
DisclosureSEC source: 0002013623-26-000010 · primarydocument.xml · nonDerivative · entry 1 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,437 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 21:02 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,438 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0002013623-26-000008 · primarydocument.xml · derivative · entry 3 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,875 Underlying: Common Stock · 2,438 shares Expires 2035-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at January 3, 2026 and the remainder ratably, on a monthly basis, over the remaining three years. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 21:02 UTC | EyePoint, Inc. EYPT · Entity 5702 | SaleCommon Stock | 2,438 | $17.87 | $43,571.69 |
DisclosureSEC source: 0002013623-26-000008 · primarydocument.xml · nonDerivative · entry 2 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.22 to $18.45. The reporting person undertakes to provide EyePoint Inc., any security holder of EyePoint Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 21:02 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 2,438 | $8.26 | $20,137.88 |
DisclosureSEC source: 0002013623-26-000008 · primarydocument.xml · nonDerivative · entry 1 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,438 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 21:07 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,437 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0002013623-26-000006 · primarydocument.xml · derivative · entry 3 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,313 Underlying: Common Stock · 2,437 shares Expires 2035-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at January 3, 2026 and the remainder ratably, on a monthly basis, over the remaining three years. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 21:07 UTC | EyePoint, Inc. EYPT · Entity 5702 | SaleCommon Stock | 2,437 | $15.00 | $36,555.00 |
DisclosureSEC source: 0002013623-26-000006 · primarydocument.xml · nonDerivative · entry 2 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 21:07 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 2,437 | $8.26 | $20,129.62 |
DisclosureSEC source: 0002013623-26-000006 · primarydocument.xml · nonDerivative · entry 1 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,437 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:07 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionStock Option (Right to Buy) · Derivative | 29,250 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0002013623-26-000004 · primarydocument.xml · derivative · entry 3 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,750 Underlying: Common Stock · 29,250 shares Expires 2035-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at January 3, 2026 and the remainder ratably, on a monthly basis, over the remaining three years. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:07 UTC | EyePoint, Inc. EYPT · Entity 5702 | SaleCommon Stock | 42,544 | $17.10 | $727,319.46 |
DisclosureSEC source: 0002013623-26-000004 · primarydocument.xml · nonDerivative · entry 2 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.68 to $17.51. The reporting person undertakes to provide EyePoint Inc., any security holder of EyePoint Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:07 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 29,250 | $8.26 | $241,605.00 |
DisclosureSEC source: 0002013623-26-000004 · primarydocument.xml · nonDerivative · entry 1 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,544 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2026 Filed Jan 6, 2026 21:47 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 19,667 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0002013623-26-000002 · primarydocument.xml · derivative · entry 5 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,333 Underlying: Common Stock · 19,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The restricted stock units vest in three ratable annual installments beginning January 3, 2026. F4 · derivative.expiration_date: The restricted stock units vest in three ratable annual installments beginning January 3, 2026. Read SEC document |
| January 03, 2026 Filed Jan 6, 2026 21:47 UTC | EyePoint, Inc. EYPT · Entity 5702 | Tax withholdingCommon Stock | 6,373 | $17.48 | $111,400.04 |
DisclosureSEC source: 0002013623-26-000002 · primarydocument.xml · nonDerivative · entry 2 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,294 F1 · price: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units. Read SEC document |
| January 03, 2026 Filed Jan 6, 2026 21:47 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 19,667 | $0.00 | $0.00 |
DisclosureSEC source: 0002013623-26-000002 · primarydocument.xml · nonDerivative · entry 1 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:47 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 171,400 | $0.00 Strike: $17.48 | $0.00 |
DisclosureSEC source: 0002013623-26-000002 · primarydocument.xml · derivative · entry 4 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,400 Underlying: Common Stock · 171,400 shares Expires 2036-01-02 F3 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at January 2, 2027 and the remainder ratably, on a monthly basis, over the remaining three years. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:47 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantRestricted Stock Units · Derivative | 85,700 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0002013623-26-000002 · primarydocument.xml · derivative · entry 3 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,700 Underlying: Common Stock · 85,700 shares Expires not disclosed F2 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning January 2, 2027. F2 · derivative.expiration_date: The restricted stock units will vest in three ratable annual installments beginning January 2, 2027. Read SEC document |
| November 11, 2025 Filed Nov 12, 2025 21:03 UTC | EyePoint, Inc. EYPT · Entity 5702 | SaleCommon Stock | 2,722 | $11.61 | $31,602.42 |
DisclosureSEC source: 0002013623-25-000005 · primarydocument.xml · nonDerivative · entry 1 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · shares: Amount sold consists of 2,722 shares acquired on January 31, 2025, pursuant to EyePoint's 2019 Employee Stock Purchase Plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.30 to $11.75. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:04 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 117,000 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0001562180-25-000230 · primarydocument.xml · derivative · entry 2 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,000 Underlying: Common Stock · 117,000 shares Expires 2035-01-03 F2 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at January 3, 2026 and the remainder ratably, on a monthly basis, over the remaining three years. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:04 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantRestricted Stock Units · Derivative | 59,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000230 · primarydocument.xml · derivative · entry 1 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,000 Underlying: Common Stock · 59,000 shares Expires not disclosed F1 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning January 3, 2026. F1 · derivative.expiration_date: The restricted stock units will vest in three ratable annual installments beginning January 3, 2026. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 22:40 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $28.00 | $0.00 |
DisclosureSEC source: 0001562180-24-002119 · primarydocument.xml · derivative · entry 1 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2034-03-01 F1 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at March 1st, 2025 and the remainder ratably, on a monthly basis, over the remaining three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.